LoginCreate an account

  Username: Password:
 
Error
  • Error loading feed data.
Home

Merck, Portola in $420M deal for anticlotting drug

E-mail Print PDF
User Rating: / 0
PoorBest 

WHITEHOUSE STATION, N.J. (AP) — Merck & Co. and Portola Pharmaceuticals Inc. say they have an exclusive deal to develop and market an experimental drug to prevent strokes in people with a dangerous irregular heart rhythm.

Merck, the world's eighth-biggest drugmaker, will pay Portola $50 million initially to license the drug, called betrixaban.

The drug prevents blood clots by blocking a clotting substance called Factor Xa. The pill would be taken daily by people with atrial fibrillation, a sometimes deadly abnormal heart rhythm.

Betrixaban is currently in mid-stage testing. Merck would cover costs of future testing. If that goes well and the drug is approved for sale, Portola could earn up to $420 million in payments from Merck, plus sales royalties.

 

Copyright 2009 The Associated Press.

 

 
FOX News
FOXNews.com - Breaking news and video. Latest Current News: U.S., World, Entertainment, Health, Business, Technology, Politics, Sports.
FOX News
  • Try These Fertility Boosters
    Health news from AskDrManny Getting pregnant isn't always easy, but there are ways to give yourself a fertility boost when trying to conceive. I recently spoke with Dr. Pina LoGuidice from InnerSource Health on Long Island, N.Y. It's important to become healthy the year before attempting to conceive. Don't worry if it doesn't happen right away -- six to eight months is […] The post Try These Fertility Boosters appeared first on AskDrManny.
  • 8 tips for grilling safely
    Every year, the arrival of summer marks the unofficial beginning of grilling season.
  • Should you ice a sprained ankle?
    If you've ever suffered a sprain, you're no doubt familiar with RICE—which stands for rest, ice, compression, and elevation.

Search...

WebSite

mySSnews Login



User Menu